Definium Therapeutics

Yesterday, our team met in the nation's capital with lawmakers, clinical researchers and advocates to discuss the ongoing research in psychedelic medicines and what the future holds for these treatments. The conversation made one thing clear: innovation in psychiatry is accelerating, and continued collaboration across science, policy, and advocacy will be critical to expanding access to new treatment options for patients. As we continue to forge a new era of psychiatry, conversations like these are accelerating the momentum and we’re proud to be at the forefront in advancing mental health progress for the more than 50 million people suffering from generalized anxiety disorder (GAD) and major depressive disorder (MDD). Thank you to The Hill for hosting this event, the exceptional speakers who shared their perspectives including Rep. Jack Bergman (R-MI), John Eaton, Mary Giliberti, Matthew Strait, Stephanie Fagan, Bill Sammon, Brie Jackson, Tiffany Farchione and everyone who joined in person and online. Check out the event replay here: https://bit.ly/4v44QOR Photography credit: Kristoffer Tripplaar #MentalHealth #HealthcareInnovation #TheHillHealth #DefiniumTherapeutics #Psychedelics

Today, at the American Psychiatric Association Annual Meeting, we presented scientific posters that included pre-clinical safety details on our investigational psychedelic treatment option.    For a deeper dive into our contributions at APA and Definium's pioneering work, see here: https://bit.ly/4udAZ6l and here: https://bit.ly/3PjlxXh #APA2026 #Definium #PsychedelicMedicine #ClinicalResearch #MentalHealth 

We are proud to announce that the first patient has been dosed in Ascend, our second Phase 3 pivotal study in major depressive disorder (MDD). For more details, check out the press release here: https://lnkd.in/g67rjDsE

The Definium Team, in partnership with The Hill, invites you to the “Rethinking Psychedelic Treatment” forum on May 19th to hear from speakers including Rep. Jack Bergman (R-MI), John Eaton, Mary Giliberti, Matthew Strait, Stephanie Fagan, Bill Sammon and Brie Jackson. It’s Mental Health Awareness Month, and we are excited to discuss the potential for new options.    This forum will explore late-stage clinical trials advancing psychedelic medicines and their potential to shape the future. We’ll discuss what the data tells us and what actions Congress can take to help support responsible innovation and patient access.    For more information and registration, visit the event website: https://lnkd.in/eNgtPatu    #MentalHealth #HealthcareInnovation 

What an inspiring evening. Definium Therapeutics was honored to sponsor the American Foundation for Suicide Prevention 37th Annual Lifesavers Gala. As we advance potential treatments for major depressive disorder (MDD), generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD), we remain deeply aware of the profound impact these conditions can have on individuals, families, and communities, including their connection to suicidality. We are proud to support AFSP’s critical work to advance awareness, education, advocacy, and hope for those affected by mental health conditions. #AFSPLifesavers #Definium

We are excited to announce our 2026 financial results and business highlights from Q1, reflecting on our ongoing momentum and dedication to bringing new hope for those battling mental health disorders. Please see here for details: https://bit.ly/4uASRYI #InvestorRelations #MentalHealth #Neuroscience #HealthcareInnovation

#Sponsored Many psychiatrists agree that a walk in the sunshine is a powerful and underrated tool for improving mood, sleep and overall well-being.  What’s another thing psychiatrists agree on? The potential of certain psychedelics, like LSD, in mental health care. Join Rakesh Jain, MD, MPH, who we are proud to be partnering with, on his evening walk as he dives into the “Science of LSD”. In this video, Dr. Jain explores what we know about pharmaceutical LSD, including its potential role in neuroplasticity. He underscores how modern research is crucial to understanding its potential in mental health. Learn more: https://bit.ly/49HJOME  #MentalHealthInnovation #DefiniumTheraputics #Biotech #Neuroscience #BrainHealth #ReroutingMinds

May is Mental Health Awareness Month – a time to recognize the challenges that millions of adults in the U.S. experience and promote mental wellness nationwide. Join us throughout the month as we share more about our efforts to develop potential novel treatments using pharmaceutical LSD for generalized anxiety disorder (GAD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD) to broaden our impact and bring new hope to individuals profoundly affected by the current mental health crisis. Together, we are working towards the future of psychiatry.  #MentalHealthAwarenessMonth #MHAM #BrainHealth #MentalHealth 

We used to call it "Bland Diego." Until it wasn't.... When you did you get classy San Diego? Sixth largest market in the US. Over 1500 companies with $20M+ revenue (so 1500+ CFOs). Even biotechs working in psychedelics. Wait. What? Join us today (April 30) for CFO Focus San Diego featuring CNBC alum Jane Wells interviewing Anchi Chern, Group CFO at TEAM Services Group (a private co with 130,000 employees); Jill Howe, CFO at Lineage Cell Therapeutics (NYSE:LCTX) (Clinical stage biotech, $400M market cap); and Brandi Roberts, CFO at Definium Therapeutics (NASDAQ:DFTX) the late stage, psychedelic focused biotech with a $2.2B market cap. CFOs and GCs only please. Learn more and register at www.cfofocus.org Don't worry. We won't test anything on you. The mushoom apps are just portabella - we promise! #cfogcfocussandiego

We will report our first quarter 2026 financial results and business highlights during a live webcast at 4:30 p.m. EST on May 7, 2026. For more details and to register, see press release here: https://bit.ly/42EE03k